Using GLP-1s for weight loss, maintenance after bariatric surgery
UC expert recommends clinicians, patients revisit lifestyle recommendations first
Bariatric surgery has become a cornerstone treatment for severe obesity and its related comorbidities, offering superior long-term efficacy compared with lifestyle and pharmacologic interventions alone. Yet, as MedCentral recently reported, persistent clinical gaps remain in a subset of patients, including insufficient weight loss and postoperative weight regain.
Although revisional surgery is commonly considered the go-to option for inadequate weight loss or anatomical failure, it carries higher complication and mortality risks than primary bariatric procedures.
Emerging evidence positions GLP-1s as safe and effective therapeutic options with the potential to complement surgical outcomes and improve long-term weight management post-bariatric surgery.
“Clinicians should first direct patients to re-engage their obesity medicine or bariatric surgery team as they may benefit from revisiting lifestyle and post-bariatric dietary recommendations,” said Inuk Zandvakili, MD, PhD, a gastroenterologist and assistant professor of medicine at the University of Cincinnati College of Medicine.
Numerous studies support the use of GLP-1s in the post-bariatric surgery population, however, there are no standardized guidelines for their use.
Zandvakili noted that while GLP-1s have revolutionized medical weight loss, many patients may gain more durable and affordable long-term benefit from surgical or endoscopic revisions.
“The options available to the patient depend on which initial bariatric surgery they received, however, [in the absence of evidence-based guidelines] the physician should evaluate the patient and tailor further lifestyle recommendations, medications, endoscopic procedures or surgeries to their individual situation,” said Zandvakili.
He also noted that the primary contraindications for GLP-1 use post-bariatric surgery align with standard practice guidance for treatment with GLP-1 drugs, including gastrointestinal disorders and symptoms.
Featured image at top: Band shown on replica stomach 3D model. Photo/iStock/Capifrutta.
Related Stories
Phenols, found in many products, could upset heart's rhythms
October 7, 2024
Chemicals called environmental phenols include food preservatives, plastics ingredients such as BPA and the parabens in shampoos, so they are ubiquitous in everyday life. Now, University of Cincinnati research suggests that higher exposure to phenols might trigger changes in the heart's electrical system and rhythms.
Researchers work to make blood cancer a manageable disease
September 17, 2025
During Blood Cancer Awareness Month, Spectrum News and MSN highlighted researchers in the University of Cincinnati Cancer Center’s Leukemia and Drug Development Lab working to make blood cancer a manageable illness and bring new treatments to patients more efficiently than ever before.
Nephrologists miss opportunities to discuss contraceptive use with women with chronic kidney disease
November 7, 2025
Discussions about contraceptive use for women with chronic kidney disease are often avoided by nephrologists, according to University of Cincinnati data presented this week at the American Society of Nephrology's Kidney Week global. meeting in Houston. Nephrologists reported that they see the importance of reproductive health but feel ill-equipped to discuss it with patients. Discomfort, limited training and confusing guidance were among the key barriers to discussions.